title: DNA Recognition by a Novel Bis-Intercalator, Potent Anticancer Drug XR5944.
abstract: XR5944 is a potent anticancer drug with a novel DNA binding mode: DNA bisintercalationg with major groove binding. XR5944 can bind the estrogen response element (ERE) sequence to block ER-ERE binding and inhibit ERα activities, which may be useful for overcoming drug resistance to currently available antiestrogen treatments. This review discusses the progress relating to the structure and function studies of specific DNA recognition of XR5944. The sites of intercalation within a native promoter sequence appear to be different from the ideal binding site and are context- and sequence- dependent. The structural information may provide insights for rational design of improved EREspecific XR5944 derivatives, as well as of DNA bis-intercalators in general.
authors: Clement
authors: C
authors: Lin
authors: College of Pharmacy, University of Arizona, 1703 E. Mabel St, Tucson, AZ 85721, USA. yang@pharmacy.arizona.edu.
authors: Danzhou
authors: D
authors: Yang
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology*; D004273:DNA, Neoplasm / Q000737:chemistry* / Q000187:drug effects*; D047628:Estrogen Receptor alpha / Q000037:antagonists & inhibitors / Q000378:metabolism; D015394:Molecular Structure; D010619:Phenazines / Q000737:chemistry* / Q000494:pharmacology*; D020218:Response Elements / Q000187:drug effects; D013329:Structure-Activity Relationship
chemical_list: D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; C506487:ESR1 protein, human; D047628:Estrogen Receptor alpha; D010619:Phenazines; C434883:XR5944